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Introduction
Chest pain is one of the most frequent and chal-
lenging clinical settings in emergency departments 
worldwide [1]. While the diagnosis and subsequent 
optimal management in ST segment elevation myocar-
dial infarction (STEMI) are well established, rapid diag-
nosis of patients without persistent ST-segment eleva-
tion on ECG remains a challenge. Current guidelines on 
diagnosis and treatment of STEMI and non-ST-segment 
elevation acute coronary syndrome (non-STEACS) em-
phasize maximal shortening of time to diagnosis and 
treatment in high-risk patients [2–4]. Available tools 
are effective but time consuming. It is recommended 
to measure cardiac troponin, a gold standard mark-
er of myocardial damage, in serial blood samples [3]. 
Copeptin, the C-terminal part of the prohormone for 
vasopressin, is emerging as a marker of acute endog-
enous stress. Due to its characteristic release pattern 
with an immediate increase a few minutes after symp-
tom onset, together with cardiac troponin, a marker 
specific for myocardial injury, it could fill the gap and 
effectively shorten the time to diagnosis. Also in the 
context of early risk stratification crucial for optimal 
management, copeptin has high potential to be a rapid 
information tool [5, 6].
Below, we present the design of the COPACS (COPep- 
tin for Acute Coronary Syndrome) Study, whose aim is to 
assess the role of copeptin in diagnosis and prediction 
of adverse events in a population of patients with chest 
pain without persistent T-segment elevation on ECG al-
ready at presentation, with regard to high-sensitive tro-
ponin T (hs-TnT).
General information 
COPACS is a prospective observational study of the 
diagnostic and prognostic performance of copeptin in 
patients presenting to the Emergency Department with 
chest pain without persistent ST-segment elevation on 
ECG (non-conclusive ECG). Enrollment is conducted in 
the 2nd Department of Cardiology, Zabrze, Medical Uni-
versity of Silesia, Katowice, Poland and is planned to be 
held in two rounds: 1) between December 15, 2011 and 
December 31, 2013, 2) between October 01, 2015 and 
December 31, 2016. Patients are enrolled according to 
prespecified inclusion and exclusion criteria (Table I).
Criteria of 6-hour chest pain was set as a result of 
previously published data on the profile of copeptin re-
lease in patients with acute coronary syndromes, which 
indicate rapid release with peak concentrations at 1–2 h 
from symptom onset followed by a decrease to the nor-
mal range up to 5–6 h [7]. This strategy follows guide-
line-recommended efforts for maximal shortening of the 
time from symptom onset to diagnosis and treatment in 
this group of patients.
Sample size. Based on retrospective analysis of pa-
tients admitted to the Emergency Department of the 
enrolling center in the 6-month period preceding the 
start of enrollment, the predicted number of included pa-
tients is 6–8 per month, which corresponds to a rate of 
144–192 participants in the first round of enrollment and 
234–312 participants at the end of recruitment.
Study chart
After inclusion, each patient undergoes initial clini-
cal examination which includes physical examination, 
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12-lead electrocardiogram (ECG), echocardiographic ex-
amination, and standard laboratory tests (blood count, 
sodium, potassium, creatinine, glomerular filtration rate 
(GFR), C-reactive protein, and N-terminal pro-B type na-
triuretic peptide (NT-proBNP)). High-sensitive troponin T, 
creatine kinase myocardial bound (CK-MB) and copeptin 
are measured at admission (T0). The initial diagnosis is 
established by the emergency physician and is verified 
by the supervisor cardiologist based on available data 
and ESC guidelines [3]. All patients are stratified accord-
ing to the GRACE 1.0 risk score. Hs-TnT and CK-MB are 
measured afterwards at 6 h (T6) and repeated according 
to clinical indications. Furthermore, all included patients 
undergo routine diagnostic and therapeutic procedures 
as indicated in the ESC guidelines for non-STEACS [3]. De-
pending on the findings of myocardial necrosis markers 
and based on clinical judgment of the treating physician, 
the patient is qualified for a treadmill stress test or di-
rectly for a coronary angiogram (Figure 1).
Measurement of copeptin
Copeptin is measured from the blood sample drawn at 
admission (T0) and stored according to the instructions 
of the manufacturer. The result is double-blinded until 
completion of one-year follow-up. The measurement is 
performed using the BRAHMS Copeptin KRYPTOR assay 
on a BRAHMS KRYPTOR compact plus analyzer (BRAHMS 
GmbH, Hennigsdorf, Germany) with the limit of detection 
4.8–500 pmol/l, 97.5th percentile for healthy population 
17.4 pmol/l, 20% coefficient of variation 12 pmol/l. Co-
peptin is regarded as positive when > 17.4 pmol/l, as rec-
ommended by the producer.
Measurement of troponin
Troponin used throughout the study is high-sensitive 
troponin T (hs-TnT). Measurement is carried out at ad-
mission (T0), after 6 h from admission (T6) and at further 
time points according to clinical indications and the deci-
sion of the treating physician. High-sensitive troponin T 
is measured with electrochemiluminescent technology 
using the Elecsys Troponin T hs STAT assay (limit of de-
tection 3–10 000 ng/l, 99th percentile for healthy popu-
lation 14 ng/l (95% CI: 12.7–24.9 ng/l), 10% coefficient 
of variation 13 ng/l) on a cobase 411 analyzer (Roche 
Diagnostics GmbH, Mannheim, Germany). High-sensi-
tive troponin T is regarded as positive when ≥ 14 ng/l, 
according to the manufacturer’s indications and guide-
lines [3].
Adjudicated final diagnosis
Final diagnosis of non-ST-elevation myocardial infarc-
tion (NSTEMI), unstable angina (UA) or other causes of 
chest pain is established according to the independent 
opinions of two cardiologists, blinded to the copeptin re-
sult, after analysis of all available data and tests gathered 
during the hospital stay. In case of incoherence of their 
diagnosis, a third cardiologist is asked for an opinion.
Follow-up
Patients are monitored during a five-year period with 
clinical assessment conducted at discharge, 6 months, 
1 year and 5 years. At 6-month and 5-year follow-up infor-
Table I. Inclusion and exclusion criteria
Inclusion criteria:
•	chest pain lasting 5 min or more
•	beginning of symptoms in last 6 h before admission
Exclusion criteria:
•	STEMI
•	end-stage renal insufficiency (defined as GFR < 15 ml/min/1.73 m2 
and/or dialysis)
•	anemia (defined as level of hemoglobin < 10 g/dl for men;  
< 8 g/dl for women)
•	hyponatremia (defined as level of Na+ < 125 mmol/l)
•	injury or major surgery in last 4 weeks
•	cancer with predicted life duration < 6 months
•	pregnancy
•	age < 18 years
•	lack of informed consent 
STEMI – ST-segment elevation myocardial infarction, GFR – glomerular filtration 
rate.
Figure 1. Study chart
T0 – admission time, T6 – 6  h after admission, CK-MB – creatine 
kinase myocardial bound, NT-proBNP – N-terminal pro-B-type natri-
uretic peptide, hs-TnT – high-sensitive troponin T.
Hs-TnT < 14 ng/l Hs-TnT ≥ 14 ng/l
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mation on Canadian Cardiovascular Society (CCS) class, 
New York Heart Association (NYHA) class and occurrence 
of study endpoints is collected in a phone call. One-year 
follow-up is conducted as a visit to the outpatient unit 
and involves physical examination, 12-lead ECG, echocar-
diogram, CCS and NYHA class determination, the blood 
test for NT-proBNP and information on the occurrence 
of study endpoints. If the phone contact fails, medical 
records of the enrolling center will be screened. If no in-
formation is found, national health care provider sources 
will be used to obtain information on hospitalization and 
endpoint occurrence.
Endpoints
All events are adjudicated by a cardiologist blinded to 
copeptin results. The primary diagnostic endpoint is the 
final diagnosis of NSTEMI. 
The primary prognostic endpoint is defined as death 
of cardiovascular origin. The secondary prognostic end-
point is defined as major adverse cardiac and cerebrovas-
cular events (MACCE) and includes death of cardiovas-
cular origin, non-fatal acute myocardial infarction (AMI), 
UA, repeated cardiac revascularization, and stroke. 
Acute myocardial infarction is defined according to 
the third universal definition [8]. Repeated cardiac revas-
cularization is defined as percutaneous coronary inter-
vention or coronary artery bypass grafting on the vessel 
or lesion responsible for ACS at the moment of enroll-
ment.
Definitions
Admission ECG is defined as non-conclusive if no 
persistent ST-segment elevation fulfilling the criteria of 
ST-segment elevation is present. ST-segment changes 
(ΔST) are defined as depression of the ST segment of 
≥ 1 mm or non-persistent (< 20 min) elevation of the ST 
segment of ≤ 1 mm or T wave reversal > 2 mm, each of 
these in at least two contiguous leads in 12-lead ECG. 
Coronary artery disease is diagnosed in the coronary an-
giogram if the stenosis of the coronary artery is > 50%. 
Maximal hs-TnT and maximal CK-MB are defined as the 
maximal concentrations of the biomarkers measured 
during the hospital stay.
Statistics
Continuous variables are presented as mean ± stan-
dard deviation or median (interquartile range) and are 
compared with Student’s t test or the Mann-Whitney 
U test and ANOVA or Kruskal-Wallis test, depending on 
their distribution. Categorical variables are presented as 
n (%) and are compared with the c2 test. Spearman and 
Pearson methods are used for calculating the correlation 
of copeptin with continuous and categorical variables, re-
spectively. Follow-up is planned to be continued until oc-
currence of an endpoint or up to 5 years from enrollment. 
Survival curves and MACCE-free curves for copeptin, 
hs-TnT and their combinations are performed with the 
Kaplan-Meier method. Diagnostic accuracy of copeptin, 
hs-TnT and their combination for prediction of endpoints 
is presented as receiver operating characteristic (ROC) 
curves. Areas under the curve (AUC) are compared with 
the z test. The influence of biomarkers and preselected 
baseline clinical and procedural parameters on the oc-
currence of endpoints is calculated with uni- and multi-
variable Cox proportional hazard regression models.
A novel statistical method – taxonomy – will be used 
to evaluate the predictive accuracy of copeptin. The addi-
tional value of taxonomy over commonly used regression 
models is the ability to identify a subgroup of patients 
with the highest risk in relation to the studied variable 
(here copeptin) regarding the defined study endpoint. As 
previously described [9], taxonomy is a form of multivar-
iate analysis based on correlation of prespecified vari-
ables. As a result it provides clusters, groups of patients 
with minimal intragroup similarities and maximal inter-
group differences in parameters, defined by “distance”. 
According to Marczewski and Steinhaus [10], the dis-
tance equals the symmetric difference between patients 
in studied variables. With defined distance between 
variables, linkage methods are used to link sufficiently 
similar clusters together, to finally form a classification 
tree, a dendrogram. This graphic presentation of multi-
dimensional space of patients and variables is regarded 
to be useful in identification of factors predictive for vari-
ables differentiated in this model. Intercluster differences 
in studied parameters are analyzed with one-tailed vari-
ance, and the Mann-Whitney U test is used for analogous 
analysis of the endpoint.
The p-value of < 0.05 will be assumed significant 
throughout the analysis. All analyses are performed with 
Statistica software 10 (StatSoft Inc., Tulsa, OK, USA), 
GraphPad Prism 6.00 (GraphPad, La Jolla, California, USA) 
and platform R, v. 3.0.2 (R Foundation for Statistical Com-
puting, Vienna, Austria).
Ethics 
The study received approval from the Ethical Com-
mittee of the Medical University of Silesia (decision no. 
KNW/0022/KB1/187/11) and is conducted according to 
the policy of the Declaration of Helsinki. All patients who 
met the inclusion criteria gave their informed consent 
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